Dolutegravir superior to standard-of-care treatment in children and adolescents
Dolutegravir-based treatment was superior to treatment based on efavirenz or a boosted protease inhibitor in children and adolescents, both as first-line or second-line treatment, a large international study has concluded. Dr Anna Turkova of the United Kingdom Medical Research Council presented the 96-week results of the ODYSSEY study at the 2021 virtual Conference on Retroviruses… Read More »